{"title":"Changes in haemostasis and proteins of the acute phase following cardiac surgery.","authors":"J Kvasnicka, Z Krska, I Vacková, J Tosovský","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>After cardiac surgery performed with extracorporeal circulation (ECC) involving heart valve prostheses (PHVS, n 12) and after a bypass of the coronary arteries by a venous graft (CABG, n 19), the authors investigated the dynamics of changes of haemostasis on the 1st, 3rd, 6th, 10th and 21st day after operation. As anti-thrombotic treatment after PHVS anticoagulants were used, after CABG thrombocyte inhibitors. On the 1st day after operation in both groups thrombocytes decline, while after the 10th day their numbers increase. From the 6th day there is in both groups a rise of fibrinogen and other proteins of the acute phase (alpha-1-antitrypsin, orosomucoid and ceruloplasmin, while there was a drop of transferrin. On the 3rd and 6th day after operation fibrinolysis activators decline (euglobulin fibrinolysis). These findings suggest an increased risk of thrombophilia during the postoperative period and are probably associated with the release of interleukin-1 after Ecc and the stress of cardiac surgery. In patients with CABG on the 1st day a major drop of thrombocytes occurs, on the 6th day an elevated fibrinogen value was recorded and on the 10th day a reduced fibrinolytic activity, as compared with patients with PHVS. These changes will be, however, associated rather with a greater development of general atherosclerosis in patients with CABG, which leads to a further alteration of haemostasis, rather than with the applied antithrombotic treatment.</p>","PeriodicalId":75772,"journal":{"name":"Czechoslovak medicine","volume":"13 4","pages":"213-26"},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Czechoslovak medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
After cardiac surgery performed with extracorporeal circulation (ECC) involving heart valve prostheses (PHVS, n 12) and after a bypass of the coronary arteries by a venous graft (CABG, n 19), the authors investigated the dynamics of changes of haemostasis on the 1st, 3rd, 6th, 10th and 21st day after operation. As anti-thrombotic treatment after PHVS anticoagulants were used, after CABG thrombocyte inhibitors. On the 1st day after operation in both groups thrombocytes decline, while after the 10th day their numbers increase. From the 6th day there is in both groups a rise of fibrinogen and other proteins of the acute phase (alpha-1-antitrypsin, orosomucoid and ceruloplasmin, while there was a drop of transferrin. On the 3rd and 6th day after operation fibrinolysis activators decline (euglobulin fibrinolysis). These findings suggest an increased risk of thrombophilia during the postoperative period and are probably associated with the release of interleukin-1 after Ecc and the stress of cardiac surgery. In patients with CABG on the 1st day a major drop of thrombocytes occurs, on the 6th day an elevated fibrinogen value was recorded and on the 10th day a reduced fibrinolytic activity, as compared with patients with PHVS. These changes will be, however, associated rather with a greater development of general atherosclerosis in patients with CABG, which leads to a further alteration of haemostasis, rather than with the applied antithrombotic treatment.
在心脏瓣膜假体(PHVS, n 12)和冠状动脉静脉搭桥(CABG, n 19)行体外循环(ECC)心脏手术后,作者观察了术后第1、3、6、10和21天的止血动态变化。作为抗血栓治疗后,PHVS使用抗凝剂,CABG后使用血栓细胞抑制剂。术后第1天两组血小板数量均下降,术后第10天血小板数量增加。从第6天开始,两组急性期纤维蛋白原和其他蛋白(α -1-抗胰蛋白酶、orosomucoid和铜蓝蛋白)升高,而转铁蛋白下降。术后第3、6天纤维蛋白溶解激活剂下降(优球蛋白纤维蛋白溶解)。这些发现表明,术后期间血栓形成的风险增加,可能与Ecc后白细胞介素-1的释放和心脏手术的压力有关。与PHVS患者相比,CABG患者在第1天出现血小板显著下降,第6天纤维蛋白原值升高,第10天纤维蛋白溶解活性降低。然而,这些变化与冠状动脉搭桥患者更大程度的一般性动脉粥样硬化相关,从而导致止血功能的进一步改变,而不是与应用抗血栓治疗相关。